Synopsis
Synopsis
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-
2. Alpha 6 Deoxyoxytetracycline
3. Alpha-6-deoxyoxytetracycline
4. Atridox
5. Bmy 28689
6. Bmy-28689
7. Bmy28689
8. Bu 3839t
9. Bu-3839t
10. Bu3839t
11. Doxycycline
12. Doxycycline Calcium
13. Doxycycline Calcium Salt (1:2)
14. Doxycycline Chinoin
15. Doxycycline Hemiethanolate
16. Doxycycline Hyclate
17. Doxycycline Monohydrate
18. Doxycycline Monohydrochloride, 6 Epimer
19. Doxycycline Monohydrochloride, 6-epimer
20. Doxycycline Monohydrochloride, Dihydrate
21. Doxycycline Phosphate (1:1)
22. Doxycycline-chinoin
23. Hydramycin
24. Oracea
25. Periostat
26. Vibra Tabs
27. Vibra-tabs
28. Vibramycin
29. Vibramycin Novum
30. Vibravenos
1. Doxycycline Hyclate
2. 24390-14-5
3. Atridox
4. Periostat
5. Vibra-tabs
6. Doxyprex
7. Monodoks
8. Tetraclean
9. Doxy-lemmon
10. Doxychel Hyclate
11. Vibramycin
12. Acticlate
13. Mespafin
14. Tetradox
15. Doxy
16. Doxycycline Hydrochloride Hemiethanolate Hemihydrate
17. Retens
18. Doxicrisol
19. Vibraveineuse
20. Vibravenos
21. Azudoxat
22. Clinofug
23. Diocimex
24. Duradoxal
25. Granudoxy
26. Ronaxan
27. Zadorin
28. Spanor
29. Unacil
30. Acticlate Cap
31. 19xts3t51u
32. Nsc-741421
33. 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride, Compound With Ethyl Alcohol (2:1), Monohydrate
34. Vivox
35. 6-deoxy-5-hydroxytetracycline Hydrochloride Hemihydrate
36. (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;ethanol;hydrate;dihydrochloride
37. Dentista
38. Doxteric
39. Doxy 100
40. 10592-13-9
41. Mfcd07357237
42. Doxy 200
43. Doxycycline Hyclate (internal Use)
44. Unii-19xts3t51u
45. Doryx Mpc
46. Doxycycline Hyclate [usan:usp]
47. Doxycyclini Hyclas
48. Periostat (tn)
49. (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;ethanol;hydrate;dihydrochloride
50. Vibra-tabs (tn)
51. Lymepak (tn)
52. Doxylar
53. Lymepak
54. Doryx (tn)
55. Wc 2031
56. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, Hydrochloride, (4s,4ar,5s,5ar,6r,12as)-, Compd. With Ethanol, Hydrate (2:2:1:1)
57. Doxycycline Hyclate (usp)
58. Chembl3989740
59. Doxycycline Hyclate [vandf]
60. (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide Compound With Ethanol (2:1) Dihydrochloride Hydrate
61. Amy32700
62. Doxycycline Hyclate [usp-rs]
63. Doxycycline Hyclate [who-dd]
64. Doxycycline Hyclate [who-ip]
65. S4163
66. Wc2031
67. Akos025402170
68. Ac-6017
69. Ccg-270611
70. Ds-9077
71. Nsc 741421
72. Doxycycline Hyclate [green Book]
73. Doxycycline Hyclate [ep Impurity]
74. Doxycycline Hyclate [orange Book]
75. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, Monohydrochloride, Compd. With Ethanol (2:1), Monohydrate, (4s-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-
76. 2-naphthacenecarboxamide, 4beta-(dimeethylamino)-1,4,4abeta,5,5abeta,6,11,12a-octahydro-3,5beta,10,12,12abeta-pentahydroxy-6beta-methyl-1,11-dioxo-, Monohydrochloride, Compd. With Ethyl Alcohol (2:1), Monohydrate
77. Bd166236
78. Doxycycline Hyclate [ep Monograph]
79. Doxycycline Hydrochloride Hydrate (jp17)
80. Doxycyclini Hyclas [who-ip Latin]
81. Ethanol, Compd. With (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride (1:2), Monohydrate
82. Doxycycline Hyclate [usp Monograph]
83. Doxycycline, Hyclate - Cas 24390-14-5
84. Sw219440-1
85. Sw219440-2
86. D02129
87. Doxycycline Hydrochloride Hydrate [jan]
88. Doxycycline Hyclate 100 Microg/ml In Acetonitrile
89. Q27116248
90. Z2791720087
91. Doxycycline Hydrochloride Hemiethanolate Hemihydrate [mi]
92. Doxycycline Hyclate Is Known As A Broad-spectrum Tetracycline Antibiotic.
93. (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide - Ethanol (2:1) Dihydrochloride Hydrate
94. Bis((4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide) Ethanol Hydrate Dihydrochloride
| Molecular Weight | 1025.9 g/mol |
|---|---|
| Molecular Formula | C46H58Cl2N4O18 |
| Hydrogen Bond Donor Count | 16 |
| Hydrogen Bond Acceptor Count | 20 |
| Rotatable Bond Count | 4 |
| Exact Mass | 1024.3123164 g/mol |
| Monoisotopic Mass | 1024.3123164 g/mol |
| Topological Polar Surface Area | 385 Ų |
| Heavy Atom Count | 70 |
| Formal Charge | 0 |
| Complexity | 958 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 12 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 6 |
| 1 of 10 | |
|---|---|
| Drug Name | Atridox |
| Drug Label | DORYX Capsules contain specially coated pellets of doxycycline hyclate, a broad-spectrum antibiotic synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration.The structural formula for doxycycline hyclate is... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | System, extended release |
| Route | Periodontal |
| Strength | 50mg |
| Market Status | Prescription |
| Company | Tolmar |
| 2 of 10 | |
|---|---|
| Drug Name | Doryx |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | eq 100mg base; eq 80mg base; eq 200mg base; eq 150mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Mayne Pharma |
| 3 of 10 | |
|---|---|
| Drug Name | Doxy 100 |
| PubMed Health | Doxycycline (Injection) |
| Drug Classes | Antibiotic, Antimalarial, Antiprotozoal |
| Drug Label | Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and mannitol in Water for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. It is... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 100mg base/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 4 of 10 | |
|---|---|
| Drug Name | Doxy 200 |
| PubMed Health | Doxycycline (Subgingival) |
| Drug Classes | Antibacterial |
| Drug Label | Doxycycline hyclate is a broad-spectrum antibiotic synthetically derived from oxytetracycline. The structural formula is as follows:with a molecular formula of C22H24N2O8H2O and a molecular weight of 462.46. The chemical designation for doxycycline i... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 200mg base/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 5 of 10 | |
|---|---|
| Drug Name | Doxycycline hyclate |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet; Capsule, delayed release; Capsule; Tablet, delayed release |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 150mg base; eq 20mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Corepharma; Mutual Pharma; Vintage Pharms; Hikma Intl Pharms; Mylan Pharms; Blu Caribe; Ivax Sub Teva Pharms; Actavis Elizabeth; Larken Labs; Lannett; Mutual Pharm; Actavis Labs Fl; Medicis; Chartwell Life Sci; Mylan; Impax Labs; Heritage Pharms |
| 6 of 10 | |
|---|---|
| Drug Name | Doryx |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | eq 100mg base; eq 80mg base; eq 200mg base; eq 150mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Mayne Pharma |
| 7 of 10 | |
|---|---|
| Drug Name | Doxy 100 |
| PubMed Health | Doxycycline (Injection) |
| Drug Classes | Antibiotic, Antimalarial, Antiprotozoal |
| Drug Label | Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and mannitol in Water for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. It is... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 100mg base/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 8 of 10 | |
|---|---|
| Drug Name | Doxy 200 |
| PubMed Health | Doxycycline (Subgingival) |
| Drug Classes | Antibacterial |
| Drug Label | Doxycycline hyclate is a broad-spectrum antibiotic synthetically derived from oxytetracycline. The structural formula is as follows:with a molecular formula of C22H24N2O8H2O and a molecular weight of 462.46. The chemical designation for doxycycline i... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 200mg base/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 9 of 10 | |
|---|---|
| Drug Name | Doxycycline hyclate |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet; Capsule, delayed release; Capsule; Tablet, delayed release |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 150mg base; eq 20mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Corepharma; Mutual Pharma; Vintage Pharms; Hikma Intl Pharms; Mylan Pharms; Blu Caribe; Ivax Sub Teva Pharms; Actavis Elizabeth; Larken Labs; Lannett; Mutual Pharm; Actavis Labs Fl; Medicis; Chartwell Life Sci; Mylan; Impax Labs; Heritage Pharms |
| 10 of 10 | |
|---|---|
| Drug Name | Atridox |
| Drug Label | DORYX Capsules contain specially coated pellets of doxycycline hyclate, a broad-spectrum antibiotic synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration.The structural formula for doxycycline hyclate is... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | System, extended release |
| Route | Periodontal |
| Strength | 50mg |
| Market Status | Prescription |
| Company | Tolmar |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Antimalarials
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)
API SUPPLIERS
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Suanfarma, at the Core of a Better Life.
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-19
Pay. Date : 2013-08-20
DMF Number : 25955
Submission : 2012-03-29
Status : Active
Type : II
Certificate Number : R1-CEP 2014-175 - Rev 00
Issue Date : 2022-02-10
Type : Chemical
Substance Number : 272
Status : Valid
Date of Issue : 2021-09-06
Valid Till : 2020-04-22
Written Confirmation Number : WC-0305
Address of the Firm :
NDC Package Code : 47621-018
Start Marketing Date : 2021-01-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-11-16
Pay. Date : 2022-09-29
DMF Number : 36491
Submission : 2021-11-11
Status : Active
Type : II
NDC Package Code : 67698-101
Start Marketing Date : 2015-09-05
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER, FOR SUSPENSION (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12864
Submission : 1998-02-17
Status : Inactive
Type : II
Certificate Number : R1-CEP 2001-038 - Rev 02
Issue Date : 2015-03-19
Type : Chemical
Substance Number : 272
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17094
Submission : 2004-01-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18004
Submission : 2005-01-13
Status : Inactive
Type : II
Certificate Number : R0-CEP 2003-225 - Rev 00
Issue Date : 2005-04-15
Type : Chemical
Substance Number : 272
Status : Withdrawn by EDQM F...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : Complete
Rev. Date : 2013-08-07
Pay. Date : 2013-07-29
DMF Number : 13771
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13636
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-11
Pay. Date : 2012-12-11
DMF Number : 13714
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12864
Submission : 1998-02-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13370
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13321
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13492
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13455
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13716
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-14
Pay. Date : 2013-12-31
DMF Number : 13174
Submission : 1998-09-10
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Certificate Number : R1-CEP 2004-163 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2011-06-01
Type : Chemical
Substance Number : 272
Certificate Number : CEP 1996-066 - Rev 07
Status : Valid
Issue Date : 2024-07-18
Type : Chemical
Substance Number : 272
Certificate Number : R1-CEP 2001-038 - Rev 02
Status : Valid
Issue Date : 2015-03-19
Type : Chemical
Substance Number : 272
Certificate Number : R0-CEP 2003-225 - Rev 00
Status : Withdrawn by EDQM Failure to CEP pro...
Issue Date : 2005-04-15
Type : Chemical
Substance Number : 272
Certificate Number : R1-CEP 2014-175 - Rev 00
Status : Valid
Issue Date : 2022-02-10
Type : Chemical
Substance Number : 272
Certificate Number : R1-CEP 1997-002 - Rev 04
Status : Withdrawn by Holder
Issue Date : 2014-11-14
Type : Chemical
Substance Number : 272
Certificate Number : CEP 2022-336 - Rev 00
Status : Valid
Issue Date : 2024-09-25
Type : Chemical
Substance Number : 272
Certificate Number : R2-CEP 1992-018 - Rev 00
Status : Withdrawn by EDQM Failure to CEP pro...
Issue Date : 2004-02-19
Type : Chemical
Substance Number : 272
Certificate Number : R1-CEP 1999-100 - Rev 05
Status : Valid
Issue Date : 2022-05-06
Type : Chemical
Substance Number : 272
Certificate Number : R1-CEP 2000-165 - Rev 07
Status : Valid
Issue Date : 2022-04-20
Type : Chemical
Substance Number : 272
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
Suanfarma, at the Core of a Better Life.
About the Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical indu...
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.
About the Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering g...
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : A globally renowned manufacturer of Small Volume Parenterals (SVPs), Gland Pharma was founded in 1978 at Hyderabad by a visionary, PVN Raju, who has always thought far ahead of his...
About the Company : Gurvey & Berry offers an impressive lineup of bulk raw materials, but we are much more than products by the kilo or tonne. With 4 decades behind us, and our Service First philosoph...
About the Company : Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services fo...
About the Company : Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its ex...
About the Company : Spansules started in 2000 & now it is one of the leading pellets manufacturing pharmaceutical company with manufacturing facilities and R&D facilities spearheading landmark researc...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
D-PLEX100, an extended-release doxycycline hyclate formulation, is currently evaluated for preventing surgical site infections in patients undergoing abdominal colorectal surgery.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2024
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PolyPid Announces Last Patient in For SHIELD II Phase 3 Trial Evaluating D-PLEX
Details : D-PLEX100, an extended-release doxycycline hyclate formulation, is currently evaluated for preventing surgical site infections in patients undergoing abdominal colorectal surgery.
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2024
Details:
The company intends to use the net proceeds from the financing for its ongoing SHIELD IIlate-stage clinical trial studies D-PLEX100 (doxycycline hyclate) for the treatment of surgical site infections.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Citizens JMP
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 01, 2024
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Citizens JMP
Deal Size : $14.0 million
Deal Type : Private Placement
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
Details : The company intends to use the net proceeds from the financing for its ongoing SHIELD IIlate-stage clinical trial studies D-PLEX100 (doxycycline hyclate) for the treatment of surgical site infections.
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 01, 2024
Details:
D-PLEX100 is a long-release doxycycline hyclate formulation currently in late-stage trials to prevent infections after colorectal surgery.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PolyPid Enrolls 200th Patient in SHIELD II Trial for D-PLEX₁₀₀ Against Surgical Infections
Details : D-PLEX100 is a long-release doxycycline hyclate formulation currently in late-stage trials to prevent infections after colorectal surgery.
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2024
Details:
The company intends to use net proceeds for the SHIELD II phase 3 clinical trial, evaluating D-PLEX100 (extended release doxycycline hyclate) for preventing infections in colorectal surgery patients.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: JMP Securities
Deal Size: $16.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 04, 2024
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : JMP Securities
Deal Size : $16.2 million
Deal Type : Private Placement
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
Details : The company intends to use net proceeds for the SHIELD II phase 3 clinical trial, evaluating D-PLEX100 (extended release doxycycline hyclate) for preventing infections in colorectal surgery patients.
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 04, 2024
Details:
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
Details : D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2023
Details:
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2023
Details:
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀...
Details : D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 22, 2023
Details:
PolyPid intends to use the net proceeds from the Public Offering to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Newbridge Securities Corporation
Deal Size: $7.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 31, 2023
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Newbridge Securities Corporation
Deal Size : $7.1 million
Deal Type : Public Offering
Details : PolyPid intends to use the net proceeds from the Public Offering to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site ...
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 31, 2023
Details:
PolyPid intends to use the net proceeds from the Public Offering to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Newbridge Securities Corporation
Deal Size: $6.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 29, 2023
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Newbridge Securities Corporation
Deal Size : $6.2 million
Deal Type : Public Offering
Details : PolyPid intends to use the net proceeds from the Public Offering to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site ...
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 29, 2023
Details:
PolyPid intends to use the net proceeds from the private placement to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Newbridge Securities Corporation
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 29, 2023
Lead Product(s) : Doxycycline Hyclate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Newbridge Securities Corporation
Deal Size : $4.4 million
Deal Type : Private Placement
Details : PolyPid intends to use the net proceeds from the private placement to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical sit...
Brand Name : D-PLEX100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 29, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : DOXYCYCLINE HYCLATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 75MG BASE
Packaging :
Approval Date : 2017-06-14
Application Number : 208765
Regulatory Info : RX
Registration Country : USA
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : DOXYCYCLINE HYCLATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 150MG BASE
Packaging :
Approval Date : 2017-06-14
Application Number : 208765
Regulatory Info : RX
Registration Country : USA
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : DOXYCYCLINE HYCLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 50MG BASE
Packaging :
Approval Date : 1982-03-29
Application Number : 62337
Regulatory Info : DISCN
Registration Country : USA
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : DOXYCYCLINE HYCLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 100MG BASE
Packaging :
Approval Date : 1982-03-29
Application Number : 62337
Regulatory Info : DISCN
Registration Country : USA
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : DOXYCYCLINE HYCLATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 100MG BASE
Packaging :
Approval Date : 1986-04-07
Application Number : 62538
Regulatory Info : DISCN
Registration Country : USA
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : RX
Registration Country : USA
Brand Name : DOXYCYCLINE HYCLATE
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : EQ 150MG BASE
Packaging :
Approval Date : 2022-01-03
Application Number : 213075
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : DOXY 200
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 200MG BASE/VIAL
Packaging :
Approval Date : 1983-12-09
Application Number : 62475
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - EQ 150MG BASE
USFDA APPLICATION NUMBER - 205931
DOSAGE - TABLET;ORAL - EQ 75MG BASE
USFDA APPLICATION NUMBER - 205931
DOSAGE - TABLET;ORAL - EQ 100MG BASE
USFDA APPLICATION NUMBER - 209844
DOSAGE - CAPSULE;ORAL - EQ 100MG BASE
USFDA APPLICATION NUMBER - 50007
DOSAGE - CAPSULE;ORAL - EQ 50MG BASE **Federa...DOSAGE - CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50007
DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - EQ 1...DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE
USFDA APPLICATION NUMBER - 50582
DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - EQ 7...DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE
USFDA APPLICATION NUMBER - 50582
DOSAGE - SYSTEM, EXTENDED RELEASE;PERIODONTAL...DOSAGE - SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG
USFDA APPLICATION NUMBER - 50751
DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 10...DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50795
DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 12...DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50795
DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 15...DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE
USFDA APPLICATION NUMBER - 50795
DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 20...DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE
USFDA APPLICATION NUMBER - 50795
DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 50...DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50795
DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 60...DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE
USFDA APPLICATION NUMBER - 50795
DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 75...DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE
USFDA APPLICATION NUMBER - 50795
DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 80...DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE
USFDA APPLICATION NUMBER - 50795
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seqens
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vertellus
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Disintegrants & Superdisintegrants
Thickeners and Stabilizers
Controlled & Modified Release
Granulation
Parenteral
Solubilizers
Film Formers & Plasticizers
Taste Masking
Lubricants & Glidants
Co-Processed Excipients
Topical
Chewable & Orodispersible Aids
Empty Capsules
Emulsifying Agents
Rheology Modifiers
API Stability Enhancers
Surfactant & Foaming Agents
Coloring Agents
Vegetarian Capsules
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Doxycycline Hyclate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Doxycycline Hyclate, including repackagers and relabelers. The FDA regulates Doxycycline Hyclate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Doxycycline Hyclate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Doxycycline Hyclate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Doxycycline Hyclate supplier is an individual or a company that provides Doxycycline Hyclate active pharmaceutical ingredient (API) or Doxycycline Hyclate finished formulations upon request. The Doxycycline Hyclate suppliers may include Doxycycline Hyclate API manufacturers, exporters, distributors and traders.
click here to find a list of Doxycycline Hyclate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Doxycycline Hyclate DMF (Drug Master File) is a document detailing the whole manufacturing process of Doxycycline Hyclate active pharmaceutical ingredient (API) in detail. Different forms of Doxycycline Hyclate DMFs exist exist since differing nations have different regulations, such as Doxycycline Hyclate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Doxycycline Hyclate DMF submitted to regulatory agencies in the US is known as a USDMF. Doxycycline Hyclate USDMF includes data on Doxycycline Hyclate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Doxycycline Hyclate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Doxycycline Hyclate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Doxycycline Hyclate Drug Master File in Japan (Doxycycline Hyclate JDMF) empowers Doxycycline Hyclate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Doxycycline Hyclate JDMF during the approval evaluation for pharmaceutical products. At the time of Doxycycline Hyclate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Doxycycline Hyclate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Doxycycline Hyclate Drug Master File in Korea (Doxycycline Hyclate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Doxycycline Hyclate. The MFDS reviews the Doxycycline Hyclate KDMF as part of the drug registration process and uses the information provided in the Doxycycline Hyclate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Doxycycline Hyclate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Doxycycline Hyclate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Doxycycline Hyclate suppliers with KDMF on PharmaCompass.
A Doxycycline Hyclate CEP of the European Pharmacopoeia monograph is often referred to as a Doxycycline Hyclate Certificate of Suitability (COS). The purpose of a Doxycycline Hyclate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Doxycycline Hyclate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Doxycycline Hyclate to their clients by showing that a Doxycycline Hyclate CEP has been issued for it. The manufacturer submits a Doxycycline Hyclate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Doxycycline Hyclate CEP holder for the record. Additionally, the data presented in the Doxycycline Hyclate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Doxycycline Hyclate DMF.
A Doxycycline Hyclate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Doxycycline Hyclate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Doxycycline Hyclate suppliers with CEP (COS) on PharmaCompass.
A Doxycycline Hyclate written confirmation (Doxycycline Hyclate WC) is an official document issued by a regulatory agency to a Doxycycline Hyclate manufacturer, verifying that the manufacturing facility of a Doxycycline Hyclate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Doxycycline Hyclate APIs or Doxycycline Hyclate finished pharmaceutical products to another nation, regulatory agencies frequently require a Doxycycline Hyclate WC (written confirmation) as part of the regulatory process.
click here to find a list of Doxycycline Hyclate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Doxycycline Hyclate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Doxycycline Hyclate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Doxycycline Hyclate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Doxycycline Hyclate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Doxycycline Hyclate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Doxycycline Hyclate suppliers with NDC on PharmaCompass.
Doxycycline Hyclate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Doxycycline Hyclate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Doxycycline Hyclate GMP manufacturer or Doxycycline Hyclate GMP API supplier for your needs.
A Doxycycline Hyclate CoA (Certificate of Analysis) is a formal document that attests to Doxycycline Hyclate's compliance with Doxycycline Hyclate specifications and serves as a tool for batch-level quality control.
Doxycycline Hyclate CoA mostly includes findings from lab analyses of a specific batch. For each Doxycycline Hyclate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Doxycycline Hyclate may be tested according to a variety of international standards, such as European Pharmacopoeia (Doxycycline Hyclate EP), Doxycycline Hyclate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Doxycycline Hyclate USP).
LOOKING FOR A SUPPLIER?
